Belize vs Libya: Access to anti-retroviral drugs, female
Belize
51.0%
in 2024
Libya
52.0%
in 2023
Belize rank
118th
Libya rank
116th
Access to anti-retroviral drugs, female over time
- Belize
- Libya
How they compare
Libya currently reports 52.0% against 51.0% in Belize, a difference of 1.0%.
The two have swapped places 8 times across 24 shared years of data; in 2000 it was Libya ahead.
Belize ranks 118th and Libya ranks 116th of 141 countries.
Libya has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Belize | Libya | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 9.1% | 9.2% | 0.1% | Libya |
| 2010s | 37.9% | 41.6% | 3.7% | Libya |
| 2020s | 47.0% | 50.2% | 3.2% | Libya |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Belize or Libya?
- Libya, at 52.0% against 51.0% in Belize as of 2023.
- What is the difference in access to anti-retroviral drugs, female between Belize and Libya?
- 1.0%, with Libya ahead.
- How many years of comparable data are there for Belize and Libya?
- 24 years are reported by both, from 2000 to 2023.
- How do Belize and Libya rank globally for access to anti-retroviral drugs, female?
- Belize ranks 118th and Libya ranks 116th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.